While iron deficiency is the leading cause of failure to respond to treatment with EPO; it must not be forgotten that active inflammatory or infectious processes can temporarily block the response to iron therapy and, thereby, to EPO [12–14]. This evidence concerns the gene EPO and Iron deficiency anemia.